Bishop has more than 30 years’ experience in the biotechnology industry. He served previously as the chief executive of GRAIL, which was recently acquired by Illumina. From 2013 to 2018, he served as president and chief executive at Juno Therapeutics, a company he co-founded and that was acquired by Celgene. Prior to Juno, Bishop served as an executive in residence at Warburg Pincus. He currently serves as the chairman of Sana Biotechnology and as a director of Lyell Immunopharma and Agilent Technologies.